Targeting p53-MDM2 Interaction Using Small Molecule Inhibitors and the Challenges Needed to be Addressed

Abstract excerpt

MDM2 protein is the core negative regulator of p53 that maintains the cellular levels of p53 at a low level in normal cells. Mutation of the TP53 gene accounts for 50% of all human cancers. In the remaining malignancies with wild-type TP53, p53 function is inhibited through other mechanisms. Recently, synthetic small molecule inhibitors have been developed which target a small hydrophobic pocket on MDM2 to which...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Advanced Breast Cancer Therapies
• Share to Cancer-related Molecular Pathways
• Share to Epigenetics and DNA Methylation